Wedbush Weighs in on Fennec Pharmaceuticals Inc.’s Q1 2022 Earnings (TSE:FRX)

Fennec Pharmaceuticals Inc. (TSE:FRXGet Rating) – Wedbush raised their Q1 2022 EPS estimates for Fennec Pharmaceuticals in a report issued on Wednesday, April 27th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.17) for the quarter, up from their prior estimate of ($0.18). Wedbush also issued estimates for Fennec Pharmaceuticals’ Q2 2022 earnings at ($0.15) EPS, Q3 2022 earnings at ($0.15) EPS, Q4 2022 earnings at ($0.05) EPS, FY2022 earnings at ($0.54) EPS, FY2023 earnings at $0.19 EPS, FY2024 earnings at $0.74 EPS and FY2025 earnings at $1.54 EPS.

Fennec Pharmaceuticals (TSE:FRXGet Rating) last issued its earnings results on Monday, February 28th. The biopharmaceutical company reported C($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of C$4.44 by C($4.67).

Separately, Maxim Group reissued a “buy” rating and set a C$10.00 price target on shares of Fennec Pharmaceuticals in a report on Thursday, March 24th.

Shares of TSE FRX opened at C$8.00 on Monday. Fennec Pharmaceuticals has a 1-year low of C$4.95 and a 1-year high of C$13.25. The company has a debt-to-equity ratio of 31.63, a current ratio of 13.54 and a quick ratio of 12.76. The business’s fifty day moving average price is C$7.27 and its two-hundred day moving average price is C$7.56. The firm has a market capitalization of C$208.11 million and a PE ratio of -9.32.

About Fennec Pharmaceuticals (Get Rating)

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

See Also

Earnings History and Estimates for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with's FREE daily email newsletter.